04:34 AM EDT, 04/03/2024 (MT Newswires) -- FibroGen ( FGEN ) said late Tuesday it saw "encouraging" data from a Fortis Therapeutics-sponsored phase 1 study of FG-3246 for patients with metastatic castration-resistant prostate cancer whose tumors have progressed on at least one androgen receptor-signaling inhibitor.

The company said the 56-patient study showed a median radiographic progression-free survival of 8.7 months in heavily pre-treated patients who received doses of FG-3246, also known as FOR46, in the second line or later setting before chemotherapy.

The results provide evidence of "a favorable safety profile and promising clinical activity," FibroGen ( FGEN ) said.

The most frequent adverse events were consistent with other antibody drug conjugates based on the MMAE anti-mitotic agent, and included fatigue, weight loss and and peripheral neuropathy, the company said.

Price: 2.1, Change: -0.06, Percent Change: -2.78